Evidence map›Paper›PMID 41588017›Full record

ArticleNPJ breast cancer2026

Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer.

Pingting Ye, Yixuan Wen, Rui Liu, Weiqiang Gao, Qi Li, Bin Ma, Chunyan Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pingting Ye *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yixuan Wen *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Rui LiuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Weiqiang GaoSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Qi LiDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. qf.1007@163.com.
Bin MaShanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Shanghai Jiading District Central Hospital, Shanghai, China. bin.ma@outlook.com.
Chunyan DongDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. cy_dong@tongji.edu.cn.

Funding

Key Specialty Construction Project of Shanghai Pudong New Area Health Commission PWZzk2022-01Leading Talent Program by Shanghai Municipal Health Commission 2022LJ012New Quality Clinical Specialty Program of High-end Medical Disciplinary Construction in Shanghai Pudong New Area 2025-PWXZ-01Shanghai 2023 "Science and Technology Innovation Action Plan" Outstanding Academic/Technical Leader Program 23XD1402800Shanghai Leading Talent Program of Eastern Talent Plan DFYCLJ02Shanghai Pudong New Area Advanced Talent Cultivation Project of Integrated Traditional Chinese and Western Medicine PDZY-2024-0701Shanghai Pudong New Area Traditional Chinese Medicine Inheritance Innovation Development Demonstration Pilot Project Construction YC-2023-0403Special development fund for Shanghai Zhangjiang National Independent Innovation Demonstration Zone ZJ2021-ZD-007
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with a high risk of relapse and metastasis. Due to limited tumor immune infiltration in TNBC, the effectiveness of immunotherapy is constrained. In this study, analysis of human datasets (TCGA-BRCA and Kim cohorts) revealed that tumor necrosis factor superfamily member 9 (TNFSF9) and C-X-C motif chemokine ligand (CXCL9) expressions correlate with improved prognosis and enhanced immune cell infiltration. To exploit this, we engineered human umbilical cord mesenchymal stem cells (hUC-MSCs) to co-express TNFSF9 and CXCL9 (MSC-T9C9). In murine TNBC models, the engineered MSC-T9C9 recruits CD8

Identifiers

PMID41588017
PMCPMC12946315

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.